Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 14,301,210 | 13,159,980 | 14,100,270 | 15,394,410 | 12,186,370 |
| Cost of Goods | 3,507,866 | 3,672,715 | 4,334,137 | 3,988,287 | 3,397,654 |
| Gross Profit | 10,793,340 | 9,487,263 | 9,766,141 | 11,406,130 | 8,788,719 |
| Operating Expenses | 8,294,400 | 7,046,520 | 8,641,230 | 7,084,990 | 6,848,180 |
| Operating Income | 2,499,806 | 2,441,454 | 1,125,049 | 4,321,423 | 1,941,192 |
| Interest Expense | 333,695 | 208,331 | -20,767 | 265,340 | 168,010 |
| Other Income | -1,203,396 | 124,063 | -2,417,192 | 44,419 | -108,979 |
| Pre-tax Income | 962,716 | 2,357,185 | -1,271,376 | 4,100,501 | 1,664,204 |
| Income Tax | 524,378 | 491,568 | -382,631 | 794,852 | 261,096 |
| Net Income Continuous | 438,338 | 1,865,618 | -888,745 | 3,305,649 | 1,403,107 |
| Net Income Discontinuous | N/A | 30,430 | 18,726 | -23,378 | 3,072,986 |
| Minority Interests | 39,532 | 7,022 | 9,316 | 7,013 | 4,541 |
| Net Income | $398,806 | $1,889,026 | $-879,335 | $3,275,258 | $4,471,553 |
| EPS Basic Total Ops | 0.17 | 0.78 | -0.36 | 1.34 | 1.84 |
| EPS Basic Continuous Ops | 0.18 | 0.77 | -0.36 | 1.36 | 0.58 |
| EPS Basic Discontinuous Ops | N/A | 0.01 | 0.01 | -0.01 | 1.26 |
| EPS Diluted Total Ops | 0.17 | 0.78 | -0.38 | 1.34 | 1.84 |
| EPS Diluted Continuous Ops | 0.18 | 0.77 | -0.37 | 1.36 | 0.58 |
| EPS Diluted Discontinuous Ops | N/A | 0.01 | 0.00 | -0.01 | 1.26 |
| EPS Diluted Before Non-Recurring Items | 1.21 | 1.10 | 0.89 | 1.70 | 0.90 |
| EBITDA(a) | $2,499,806 | $2,441,454 | $1,125,049 | $4,321,423 | $1,941,192 |